LTR Pharma Doses First Patient in Phase Two Study of Spontan; Shares Up 4%
MT Newswires Live
Jan 22
LTR Pharma (ASX:LTP) has dosed the first patients in the phase two pharmacokinetic study of Spontan, its rapid-acting intranasal spray to treat erectile dysfunction, signaling the shift from recruitment to active data collection, according to a Thursday Australian bourse filing.
The study is evaluating single and multiple dose pharmacokinetics in around 27 healthy male participants across three cohorts, with about half aged 65 or older in line with US Food and Drug Administration geriatric guidance, per the filing.
The study remains on track, with initial data expected in the second quarter, the filing added.
The company's shares rose 4% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.